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Safety of Placebo-Controlled Trials in
Vasospastic Angina
Chahine et a] . (1) recently reported the results of a randomized
placebo-controlled trial investigating the effects of floe long-acting
dihydropyridine calcium anisigoriml amlodyine in 52 patients with
vasospastic angina . Ali :ialiYnis were in an active phase of vial'iant
angina, with angiographically documented spasm of a major coro-
nary artery and a mean number of 12 anginal attacks/week . Never-
theless, they were randomized to take amlodipine "0 mg once daily)
or placebo for 4 weeks in double-blind conditions withou, any
background prophylactic treatment . During the 4 weeks of the
study, placebo-treated patients continued to suffer from a mean of
14 to 15 anginal attacks/week, whereas the rate was reduced to 5 to
6 attacks/week in am ;odipine-treated patients .
We (2,3) have previously argued that placebo-controlled trials
should be avoided in variant angina because, during the active phase
of this syndrome, acute myocardial infarction and sudden death may
occur in up to 20% and 10% of patients, respectively, and calcium
antagonists have clearly been shown to prevent these major cardio-
vascular events (4,5) . Probably for this reason . placebo-controlled
trials are not even requested by the Food and Drug Administration
to support approval for vasospastic angina (particularly when a drug
has already been approved for stable effort angina) . The high
number of anginal attacks reported for 4 weeks by the placebo-
treated patients in the study of Chahine et a] . (1) reinforces our
arguments. In addition, 7 (26%) of their 27 placebo-treated patients
were withdrawn from the study because of "therapeutic failure ."
What actually happened to these patients was not specified by the
authors, although this information is of the greatest importance,
because such "therapeutic failures" may mean intolerable angina,
myocardial infarction or sudden death', in fact, two patients (8%) in
the amlodipine group were " . . . withdrawn from the study because
of therapeutic failure (one patient because of admission to the
hospital to rule out myocardial infarction and one as a result of
persistent intolerable angina)."
With regard to the efficacy of amlodipine, the authors conclude
that "amlodipine given once daily is efficacious . . . in the treatment
of vasospastic angina ." Although several studies in hypertension
and stable angina have shown the long duration of action of
amlodipine, the conclusion that once-daily amlodipine is aa effective
treatment for vasospastic angina is only partially supported by the
data of the Amlodipine Study 160 (1) . Although amlodipine-treated
patients experienced a reduction in the anginal attack rate from 12 to
5 attacks/week, the circadian distribution of these residual anginal
episodes is not described by the authors . In vasospastic angina,
anginal attacks are preferentiaHy grouped in the early morning
hours, and it is extremely important that any antianginal medication
be effective during this time (6) . This is particularly true for
once-daily medications, which might lose efficacy toward the end of
the dosing interval .
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Reply
Ardissino and Savonitto primarily express their concern about
performing placebo-controlled trials in vasospastic angina, and once
more they recommend instead "active-controlled trials ." Although
it is understandable that one would be concerned about using
placebo in any patient with cardiac symptoms, there is a consensus
that this is still the best way to demonstrate efficacy and safety of
newer therapy . The CAST study (I) and its results represent the best
response to questions about the ethics of performing placebo-
controlled trials in cardiac patients .
In our opinion, the concerns of Ardissino and Savonitto about
the ethics of using placebo controls in our study are totally unjusti-
fied . We strongly feel that the benefits of our choice of protocol
clearly outweigh the small and acceptable risks . The duration of the
placebo phase in our study was short and patients were closely
monitored
. If there was any significant exacerbation of symptoms
characterized as therapeutic failure, the double-blind therapy
was
stopped and patients were placed on open therapy . Our patients
represented i rather low risk group
; 75% had angiographically
normal or near normal coronary arteries . No catastrophic event
occurred during the placebo phase of our study or in the half-dozen
or more placebo-controlled trials referenced in our study and the
letter of Ardissino and Savonitto . Patients were properly info( med
of the potential risks, and our protocol was approved independently
by the 15 different institutional review boards of the centers con-
tributing to the trial
. Further, the relative protective effects of the
calcium antagonists were observed in long-term open studies hill
were never proved by controlled trials
. To our knowledge, the Food
and Drug Administration considers approval of newer therapies for
vasospastic angina on the basis of at least one controlled trial (2) .
This singular requirement may be related more to the difficulty
of
finding enough patients to enroll than to ethical concerns .
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Although seven therapeutic failures were observed during the
placebo phase of our study, nine patients had a partial or complete
spontaneous remission, thus further emphasizing the importance of
placebo controls
. With respect to our coverage of the diurnal
distribution of attacks of vasospastic angina, we believe that Sa-
vonitto and Ardissino have answered the question themselves,
acknowledging that studies in hypertension and stable angina have
demonstrated the long duration of action of amlodipine . They have
also used a similar dosing schedule in their active-controlled trial of
felodipine (3) .
Finally, we are surprised that the letter of Morikami and Yasue
(4) did not lay to rest the concerns of Savonitto and Ardissino about
placebo-controlled trials in variant angina . All things considered, we
wonder whether it would not be more justified to request long-term,
randomized, placebo-controlled trials to effective' y test the hypoth-
esis that calcium antagonists are truly protective from myocardial
infarction and sudden death in patients with variant angina than to
continue to raise questions about short-term controlled trials .
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